Paper35924232
A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
Xu HH and 3 others. Front Immunol, 2022. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes. Papers, record 35924232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35924232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Squamous Cell | Major topic |
| Uterine Cervical Neoplasms | Major topic |
| Biomarkers, Tumor | |
| Female | |
| HLA-G Antigens | |
| Humans | |
| Prognosis | |
| Tumor Microenvironment |
Source PubMed
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32699524 | SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer. | Cancer Cell Int | 2020 | https://conductscience.org/library/papers/32699524 | PubMed |
| 2 | 27997895 | Lower Expression of SPRY4 Predicts a Poor Prognosis and Regulates Cell Proliferation in Colorectal Cancer. | Cell Physiol Biochem | 2016 | https://conductscience.org/library/papers/27997895 | PubMed |
| 3 | 30531897 | Dimensionality reduction for visualizing single-cell data using UMAP. | Nat Biotechnol | 2018 | https://conductscience.org/library/papers/30531897 | PubMed |
| 4 | 28932645 | Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4. | Oncoimmunology | 2017 | https://conductscience.org/library/papers/28932645 | PubMed |
| 5 | 31164885 | The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy. | Front Immunol | 2019 | https://conductscience.org/library/papers/31164885 | PubMed |
| 6 | 25450584 | The role of signaling pathways in cervical cancer and molecular therapeutic targets. | Arch Med Res | 2014 | https://conductscience.org/library/papers/25450584 | PubMed |
| 7 | 32495519 | Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. | Cancer Sci | 2020 | https://conductscience.org/library/papers/32495519 | PubMed |
| 8 | 33160404 | Identification of an autophagy-related gene signature for survival prediction in patients with cervical cancer. | J Ovarian Res | 2020 | https://conductscience.org/library/papers/33160404 | PubMed |
| 9 | 32104259 | ERK/MAPK signalling pathway and tumorigenesis. | Exp Ther Med | 2020 | https://conductscience.org/library/papers/32104259 | PubMed |
| 10 | 30207593 | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2018 | https://conductscience.org/library/papers/30207593 | PubMed |
| 11 | 21204120 | Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. | Stat Med | 2011 | https://conductscience.org/library/papers/21204120 | PubMed |
| 12 | 29066539 | TCR-stimulated changes in cell surface CD46 expression generate type 1 regulatory T cells. | Sci Signal | 2017 | https://conductscience.org/library/papers/29066539 | PubMed |
| 13 | 34249930 | Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates With Immune Infiltration. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34249930 | PubMed |
| 14 | 17846022 | HLA-G expression in human ovarian carcinoma counteracts NK cell function. | Ann Oncol | 2007 | https://conductscience.org/library/papers/17846022 | PubMed |
| 15 | 31693397 | Extracellular vesicles as biomarkers and therapeutic targets for cancer. | Am J Physiol Cell Physiol | 2020 | https://conductscience.org/library/papers/31693397 | PubMed |
| 16 | 17569110 | Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. | Stat Med | 2008 | https://conductscience.org/library/papers/17569110 | PubMed |
| 17 | 27659144 | Perilipin 2 and Age-Related Metabolic Diseases: A New Perspective. | Trends Endocrinol Metab | 2016 | https://conductscience.org/library/papers/27659144 | PubMed |
| 18 | 21299526 | Up-regulation of HLA-G expression in cervical premalignant and malignant lesions. | Tissue Antigens | 2011 | https://conductscience.org/library/papers/21299526 | PubMed |
| 19 | 32630545 | HLA-G: A New Immune Checkpoint in Cancer? | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32630545 | PubMed |
| 20 | 27642559 | Upregulation of long noncoding RNA SPRY4-IT1 correlates with tumor progression and poor prognosis in cervical cancer. | FEBS Open Bio | 2016 | https://conductscience.org/library/papers/27642559 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42798542 | Prognostic impact of HLA-G expression in cervical squamous cell carcinoma: correlation with PD-L1 and CD8-positive tumor infiltrating lymphocytes. | Front Immunol | 2026 | https://conductscience.org/library/papers/42798542 | PubMed |
| 42724752 | A three-gene radioresistance signature predicts tumor progression in cervical cancer. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724752 | PubMed |
| 42180867 | A novel programmed-cell-death-related prognostic risk model for cervical cancer based on mitochondrial genes. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42180867 | PubMed |
| 42100295 | CERV-Score: A Hybrid Machine Learning Framework for Cervical Cancer Risk Prediction Using Integrated Clinical and Genomic Data. | Int J Telemed Appl | 2026 | https://conductscience.org/library/papers/42100295 | PubMed |
| 41821896 | The critical role of ferroptosis in thyroid cancer development and potential therapeutic implications. | Front Oncol | 2026 | https://conductscience.org/library/papers/41821896 | PubMed |
| 40747615 | Development of a Mitochondrial Permeability Transition-Driven Necrosis-Related Prognostic Signature in Cervical Cancer: Integrating Bulk Transcriptomic and Single-Cell Data. | Cancer Med | 2025 | https://conductscience.org/library/papers/40747615 | PubMed |
| 39994715 | Prognostic assessment of cervical cancer based on biomarkers: the interaction of ERRα and immune microenvironment. | Virol J | 2025 | https://conductscience.org/library/papers/39994715 | PubMed |
| 39950465 | miR-584-5p Regulates MSMO1 to Modulate the AKT/PI3K Pathway and Inhibit Breast Cancer Progression. | Protein Pept Lett | 2025 | https://conductscience.org/library/papers/39950465 | PubMed |
| 39525016 | Up-regulation of MSMO1 was associated with poor survival in cervical cancer. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/39525016 | PubMed |
| 39469714 | HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance. | Front Immunol | 2024 | https://conductscience.org/library/papers/39469714 | PubMed |
| 38919630 | The complement regulatory protein CD46 serves as a novel biomarker for cervical cancer diagnosis and prognosis evaluation. | Front Immunol | 2024 | https://conductscience.org/library/papers/38919630 | PubMed |
| 38655053 | LINC01614 is a promising diagnostic and prognostic marker in HNSC linked to the tumor microenvironment and oncogenic function. | Front Genet | 2024 | https://conductscience.org/library/papers/38655053 | PubMed |
| 38310272 | Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects. | J Transl Med | 2024 | https://conductscience.org/library/papers/38310272 | PubMed |
| 37623251 | HLA-G 14 bp Ins/Del (rs66554220) Variant Is Not Associated with Breast Cancer in Women from Western Mexico. | Curr Issues Mol Biol | 2023 | https://conductscience.org/library/papers/37623251 | PubMed |
| 37510286 | Prediction of Prognosis and Chemotherapeutic Sensitivity Based on Cuproptosis-Associated lncRNAs in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma. | Genes (Basel) | 2023 | https://conductscience.org/library/papers/37510286 | PubMed |
| 36846109 | Immunosuppression by Inflammation-Stimulated Amplification of Myeloid-Derived Suppressor Cells and Changes in Expression of Immune Checkpoint HHLA2 in Chronic Obstructive Pulmonary Disease. | Int J Chron Obstruct Pulmon Dis | 2023 | https://conductscience.org/library/papers/36846109 | PubMed |
| 36685946 | Identification of a tissue resident memory CD8 T cell-related risk score signature for colorectal cancer, the association with TME landscapes and therapeutic responses. | Front Genet | 2022 | https://conductscience.org/library/papers/36685946 | PubMed |
| 36406134 | A panel of seven immune-related genes can serve as a good predictive biomarker for cervical squamous cell carcinoma. | Front Genet | 2022 | https://conductscience.org/library/papers/36406134 | PubMed |
Genes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35924232
GET https://conductscience.org/api/papers/v1/35924232/references?page=2